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Editorial 
Monitoring of asthma inflammation by serum 
measurements of eosinophil cationic protein (ECP). 
A new clinical approach to asthma management 
The recognition of asthma as an inflammatory 
disease has led to a change in treatment strategy of 
this disease, with the widespread use of anti- 
inflammatory inhaled corticosteroids as the first 
choice to control asthma. In spite of the fact that 
inhaled corticosteroids at ordinary doses have very 
few systemic side effects, the concern by the patients 
and by the doctors of using corticosteroids as a first 
line drug is understandable. This concern may partly 
be a consequence of the lack of appreciation of the 
inflammatory nature of asthma, due to the lack of 
clinically useful tools that clearly indicate this fact, 
but also to difficulties in proper dosaging of the 
corticosteroid treatment. Thus, how do I know when 
my patient is optimally treated? In most cases 
anamnestic information in combination with simple 
lung function testing will give me a clue, although no 
single piece of such information is a useful reflection 
of the inflammatory activity going on in the lungs of 
the asthmatic. In other cases I am for several reasons 
left in the dark. Therefore there is a need for the 
development of additional tools that objectively and 
accurately reflect the disease process of the asthmatic 
lung. One such potential tool, presented by Wever 
and colleagues (1) is the blood measurement of the 
eosinophil cationic protein (ECP). 
Serum measurements of ECP have been docu- 
mented in several recent papers and have been shown 
to be related to asthma severity as measured by 
different means such as FEV,, histamine PC,,, the 
propensity to develop late asthmatic reactions after 
allergen challenge, the propensity to develop exercise- 
induced asthma etc (2,3). These studies have basically 
been cross-sectional studies and few longitudinal 
studies have been carried out in an attempt to test the 
possible practical clinical usefulness of ECP measure- 
ments in asthma on an individual basis. In the 
paper by Wever et al. (1) a group of 20 patients with 
symptomatic disease was monitored once monthly 
during a 6 month period. The patients were sub- 
grouped into three categories, one with infectious 
exacerbations, one with inflammatory exacerbations 
and one with no exacerbations. Taking all patients 
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together the authors found, in those patients who had 
elevated ECP levels, highly significant correlations 
between ECP and several indices of airflow obstruc- 
tion such as FEV, and FEV,/FVC ratio, but less 
significant correlations to histamine reactivity. More- 
over the ECP levels were much higher and fluctuated 
widely in the inflammatory exacerbation group as 
opposed to the infectious exacerbation group. The 
conclusions are that ECP measurement in serum is a 
sensitive marker of airflow obstruction in chronic 
asthma and that the elevated levels of ECP identify 
patients at risk of inflammatory exacerbations. These 
findings have important practical implications for 
the therapeutic management of chronic asthma, since 
the elevated ECP levels most likely represent 
asthmatic patients not optimally treated with inhaled 
corticosteroids. 
What are the reasons for the elevated ECP levels in 
asthmatic patients? Basically, the ECP levels reflect 
the involvement of the eosinophil granulocyte in 
the asthmatic process. This involvement has been 
documented by several studies in which increased 
numbers of eosinophils in the lungs, either measured 
as eosinophils in the bronchoalveolar lavage fluid, 
sputum samples or as seen in biopsies were shown 
(4). In fact it is generally believed that the presence of 
activated eosinophils in the lungs is one major cause 
of asthma development. It is, however, less clear by 
what means the eosinophils contribute to the devel- 
opment of asthma, although some data point to the 
fact that eosinophils, by virtue of their secretion of 
potent basic granule proteins such as ECP and by 
secretion of lipid mediators such as leukotrienes, may 
cause damage to the epithelium, induce broncho- 
constriction and induce glandular hypersecretion. 
Thus, virtually all the major pathological findings in 
asthma. 
Why do the ECP levels in serum reflect the asth- 
matic process in the lungs? In order to discuss this 
question we have to understand the mechanism 
behind the presence of ECP in serum. Thus, it should 
be understood that the serum levels of ECP are made 
up by two parts. One part is the actual circulating 
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level of ECP. This is the level of ECP found in 
EDTA-plasma, since blood drawn in the presence of 
EDTA prevents the further release of ECP from the 
eosinophils in the tube. The other part and mostly 
the major part, is the ECP that is released from the 
eosinophils after the blood has been drawn into the 
tube, since eosinophils, present in blood that contains 
no additives, are continuously and actively secreting 
their granule proteins. From this it also follows that 
the contribution of ECP to serum is dependent on 
three factors. One is the number of eosinophils in the 
blood. The second is the content of ECP of the 
eosinophil population and the third is the propensity 
of the eosinophils to secrete their ECP. Thus, raised 
or reduced serum levels of ECP could be the conse- 
quence of several causes, and these causes should be 
borne in mind in the evaluation of a given serum ECP 
level. In some cases the ECP levels are completely 
paralleled by blood eosinophil numbers. This could 
either be due to an unaltered activity of the eosino- 
phi1 population or due to a parallel change in the 
production of eosinophils in the bone marrow and in 
the activation of the eosinophil population. In other 
cases large discrepancies between blood eosinophil 
numbers and serum ECP levels are found with no 
apparent parallelity between the two components. In 
these cases the induction of eosinophil production 
and eosinophil activation are obviously dissociated. 
How can we understand these different patterns with 
the presently available knowledge of the mechanisms 
that induce eosinophilopoiesis and activation of 
mature eosinophils? One fact is that several of the 
components that are involved in the induction and 
enhancement of eosinophilopoiesis also seem to be 
involved in the activation process. From in vitro 
studies, this seems to be true for the three cytokines, 
interleukin 3 (IL-3) and 5 (IL-5) and granulocyte- 
macrophage colony stimulating factor (GM-CSF) 
(5). Therefore, when these cytokines are produced at 
increased amounts, theoretically, this should give rise 
to increased blood eosinophil numbers and to an 
increased state of activity of the mature cells. Indeed, 
the administration of GM-CSF to man induces a 
profound eosinophilia (6). However, when the serum 
ECP levels were measured only a moderate rise was 
observed, which may suggest after all that GM-CSF 
is not an activator of degranulation of mature 
eosinophils. This is compatible with other findings 
that GM-CSF is a poor activator of eosinophil 
degranulation as opposed to IL-5, which greatly 
enhances the propensity of mature eosinophils to 
secrete their ECP. One interpretation of these data is 
that GM-CSF is a necessary cytokine for eosinophil 
production but not for eosinophil activation, whereas 
IL-5 is involved in both processes. A second impor- 
tant fact is that a number of other cytokines and 
components do activate eosinophils, but have no 
effects on eosinophil production. These involve inter- 
leukin 8 (IL-8), RANTES, platelet activating factor 
(PAF), certain leukotrienes etc. Thus, depending on 
the components produced in the asthmatic process, 
the response of the eosinophil may vary. This varia- 
tion in the response of the eosinophil probably gives 
rise to the different patterns of blood eosinophil 
numbers and serum ECP levels as discussed above. 
Raised serum ECP levels may thus reflect several 
different underlying mechanisms of activation of 
eosinophils and are probably also the reasons why 
raised ECP levels are seen in a variety of different 
diseases in addition to asthma. The fascinating pos- 
sibility, however, is that by the measurements of 
serum levels of ECP we are provided with a unique 
tool to reflect eosinophil activation in vivo. This is a 
tool which has been of great value in the expansion of 
our understanding of the pathophysiology of the 
diseases in which the eosinophil is involved. However 
equally important, serum ECP measurements may 
also be used in the clinical evaluation and therapeutic 
monitoring of patients suffering from eosinophil 
involved diseases such as asthma, as is so nicely 
demonstrated by Wever et al. (1). 
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